Almost two decades of unprecedented efforts in research costing US taxpayers over $50 billion have failed to defeat Acquired Immune Deficiency Syndrome (AIDS) and have failed to explain the chronology and epidemiology of AIDS in America and Europe. The failure to cure AIDS is so complete that the largest American AIDS foundation is even exploiting it for fundraising: ‘Latest AIDS statistics – 0,000,000 cured. Support a cure, support AMFAR.’ The scientific basis of all these unsuccessful efforts has been the hypothesis that AIDS is caused by a sexually transmitted virus, termed Human immunodeficiency virus (HIV), and that this viral immunodeficiency manifests in 30 previously known microbial and non-microbial AIDS diseases. In order to develop a hypothesis that explains AIDS we have considered ten relevant facts that American and European AIDS patients have, and do not have, in common: (1) AIDS is not contagious. For example, not even one health care worker has contracted AIDS from over 800,000 AIDS patients in America and Europe. (2) AIDS is highly non-random with regard to sex (86% male); sexual persuasion (over 60% homosexual); and age (85% are 25–49 years old). (3) From its beginning in 1980, the AIDS epidemic progressed non-exponentially, just like lifestyle diseases. (4) The epidemic is fragmented into distinct subepidemics with exclusive AIDS-defining diseases. For example, only homosexual males have Kaposi's sarcoma. (5) Patients do not have any one of 30 AIDS-defining diseases, nor even immunodeficiency, in common. For example, Kaposi's sarcoma, dementia, and weight loss may occur without immunodeficiency. Thus, there is no AIDS-specific disease. (6) AIDS patients have antibody against HIV in common only by definition–not by natural coincidence. AIDS-defining diseases of HIV-free patients are called by their old names. (7) Recreational drug use is a common denominator for over 95% of all American and European AIDS patients, including male homosexuals. (8) Lifetime prescriptions of inevitably toxic anti-HIV drugs, such as the DNA chain-terminator AZT, are another common denominator of AIDS patients. (9) HIV proves to be an ideal surrogate marker for recreational and anti-HIV drug use. Since the virus is very rare (< 0.3%) in the US/European population and very hard to transmit sexually, only those who inject street drugs or have over 1,000 typically drug-mediated sexual contacts are likely to become positive. (10) The huge AIDS literature cannot offer even one statistically significant group of drug-free AIDS patients from America and Europe. In view of this, we propose that the long-term consumption of recreational drugs (such as cocaine, heroin, nitrite inhalants, and amphetamines) and prescriptions of DNA chain-terminating and other anti-HIV drugs, cause all AIDS diseases in America and Europe that exceed their long-established, national backgrounds, i.e. <95%. Chemically distinct drugs cause distinct AIDS-defining diseases; for example, nitrite inhalants cause Kaposi's sarcoma, cocaine causes weight loss, and AZT causes immunodeficiency, lymphoma, muscle atrophy, and dementia. The drug hypothesis predicts that AIDS: (1) is non-contagious; (2) is non-random, because 85% of AIDS causing drugs are used by males, particularly sexually active homosexuals between 25 and 49 years of age, and (3) would follow the drug epidemics chronologically. Indeed, AIDS has increased from negligible numbers in the early 1980s to about 80,000 annual cases in the early '90s and has since declined to about 50,000 cases (US figures). In the same period, recreational drug users have increased from negligible numbers to millions by the late 1980s, and have since decreased possibly twofold. However, AIDS has declined less because since 1987 increasing numbers of mostly healthy, HIV-positive people, currently about 200,000, use anti-HIV drugs that cause AIDS and other diseases. At least 64 scientific studies, government legislation, and non-scientific reports document that recreational drugs cause AIDS and other diseases. Likewise, the AIDS literature, the drug manufacturers, and non-scientific reports confirm that anti-HIV drugs cause AIDS and other diseases in humans and animals. In sum, the AIDS dilemma could be solved by banning anti-HIV drugs, and by pointing out that drugs cause AIDS – modeled on the successful anti-smoking campaign.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Achard, C., H. Bernard & C. Gagneux, 1909. Action de la morphine sur les proprietes leucocytaires; leuco-diagnostic du morphinisme. Bulletin et Memoires de la Societe Medicale des Hopitanx de Paris 28, 3rd Series: 958–966.
Adams, J., 1989. AIDS: The HIV Myth. St. Martin's Press, New York.
Afrasiabi, R., R.T. Mitsuyasu, K. Schwartz & J.L. Fahey, 1986. Characterization of a distinct subgroup of high-risk persons with Kaposi's sarcoma and good prognosis who present with normal T4 cell number and T4:T8 ratio and negative HTLV-III/LAV serologic results. Am. J. Med. 81: 969–973.
AIDS Weekly, 1995. Government Congressman questions funding for AIDS research. AIDS Weekly (electronic version) May 22.
AIDS Zentrum im Robert Koch Institut, 1996. 120. Bericht des AIDS Zentrum im Robert Koch Institut. AIDS Forschung 11: 47–56.
AIDS-Zentrum im Robert Koch-Institut, 1997. 125. Bericht des AIDS-Zentrum im Robert Koch-Institut ueber aktuelle epidemiologische Daten. AIDS/HIV (Quartalsbericht I/97).
Alcabes, P., E.E. Schoenbaum & R.S. Klein, 1993. Correlates of the rate of decline of CD4+ lymphocytes among injection drug users infected with the human immunodeficiency virus. Am J. Epidemiol. 137(9): 989–1000.
Alroomi, L.G., J. Davidson, T.J. Evans, P. Galea & R. Howat, 1988. Maternal narcotic abuse and the newborn. Arch. Dis. Child. 63: 81–83.
Altman, L.K., 1984. Researchers believe AIDS virus is found. New York Times, April 24, p C1, C3.
Anderson, W., 1987. Drug Smuggling. U.S. General Accounting Office, Washington, DC.
Aral, S.O. & K.K. Holmes, 1991. Sexually transmitted diseases in the AIDS era. Sci. Am. 264:(Feb.) 62–69.
Archer, C.B., M.F. Spittle & N.P. Smith, 1989. Kaposi's sarcoma in a homosexual — 10 years on. Clin. Exper. Dermatol. 14: 233–236.
Ascher, M.S., H.W. Sheppard, W. Winkelstein Jr & E. Vittinghoff, 1993. Does drug use cause AIDS? Nature (London) 362: 103–104.
Ascher, M.S., H.W. Sheppard & W. Winkelstein Jr., 1995a. AIDS-associated Kaposi's sarcoma (letter). Science 267: 1080.
Ascher, M.S., H.W. Sheppard & W. Winkelstein, 1995b, AIDS Data. Science 268: 351–352.
Ashe, A. & A. Rampersad, 1993. Days of Grace. Alfred A. Knopf, New York.
Associated Press, 1995. Study Finds Ex-Smokers Still Risk Lung Cancer. San Francisco Chroniele, May 23, p. A5.
Associated Press, 1997. S53.7 billion spent on illegal drugs in '95. San Francisco Chronicle, November 10, p. A6.
Auerbach, D.M., W.W. Darrow, H.W. Jaffe & J.W. Curran, 1984. Cluster of cases of the Acquired Immune Deficiency Syndrome patients linked by sexual contact. Am. J. Med. 76: 487–492.
Ayers, K.M., W.E. Tucker, G. Hajian & P. de Miranda, 1996. Nonclinical toxicology studies with zidovudine: acute, subacute, and chronic toxicity in rodents, dogs, and monkeys, Fundamental and Applied Toxicology 32: 129–139.
Aylward, E.H., A.M. Butz, N. Hutton, M.L. Joyner & J.W. Vogelhut, 1992. Cognitive and motor development in infants at risk for human immunodeficiency virus. Am. J. Dis. Child. 146(2): 218–222.
Bacellar, H., A. Munoz, E.N. Miller, B.A. Cohen, D. Besley, O.A. Selnes, J.T. Becker & J.C. McArthur, 1994. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. Neurology 44: 1892–1900.
Baldwin, G.C., D.P. Tashkin, D.M. Buckley, A.N. Park, S.M. Dubinett & M.D. Roth, 1997. Marijuana and cocaine impair alveolar macrophage function and cytokine production. American Journal of Respiratory and Critical Care Medicine 156: 1606–1613
Baldwin, G.C., M.D. Roth & D.P. Tashkin, 1998. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol 83(1–2): 139–147.
Balter, M., 1997. How does HIV overcome the body's T cell bodyguards? Science 278: 1399–1400.
Barre-Sinoussi, F., J.C. Chermann, F. Rey et al., 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868–871.
Bennett, A. & A. Sharpe, 1996. AIDS fight is skewed by federal campaign exaggerating risks. Wall Street Journal, May 1, p. 1, A6.
Beral, V., T.A. Peterman, R.L. Berkelman & H.W. Jaffe, 1990. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335: 123–128.
Bergling, T., 1997. All methed up, ‘doing crystal meth will lift you up until you break’. Genre, October, p. 45–47, 88.
Bessen, L.J., J.B. Greene, E. Louie, L.E. Seitzman & H. Weinberg, 1988. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. N. Engl. J. Med. 318: 708.
Bethell, T., 1996. AIDS and poppers, pp 315–323 in AIDS: Virus or Drug-Induced?, edited by P. Duesberg. Kluwer Academic Publishers, Dordrecht, Netherlands.
Blanche, S., M.-J. Mayaux, C. Rouzious et al., 1994. Relation of the Course of HIV Infection in Children to the Severity of the Disease in their Mothers at Delivery. The New England Journal of Medicine 330(5): 308–312.
Blanche, S., C. Rouzioux, M.L.G. Moscato et al., 1989. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. N. Engl. J. Med. 320: 1643–1648.
Blattner, W.A., R.C. Gallo & H.M. Temin, 1988. HIV causes AIDS. Science 241: 514–515.
Booth, W., 1988. A rebel without a cause for AIDS. Science 239: 1485–1488.
Bradbury, J., 1998. Is the honeymoon over for Viagra? Lancet 351: 1635.
Braeu, N., H.L. Leaf, R.L. Wieczorck & D.M. Margolis, 1997. Severe hepatitis in three AIDS patients treated with Indinavir. Lancet 349: 924–925.
Braun, M.M., B.I. Truman, B. Maguire, G.T. Di Ferdinando, Jr., G. Wormser, R. Broaddus & D. L. Morse, 1989. Increasing incidence of tuberculosis in a prison inmate population, associated with HIV-infection. J. Am. Med. Assoc. 261: 393–397.
Breckenridge, A., V. Kitchen & J. Derbyshire, 1997. Antiretroviral drug trials. Science 276(5318): 1481–1482.
Bregman, D.J. & A.D. Langmuir, 1990. Farr's law applied to AIDS projections. J. Am. Med. Assoc. 263: 50–57.
Brettle, R.P., 1996. Clinical features of drug use and drug use related to HIV. Int. J. STD & AIDS 7: 151–165.
Briggs, J.H., C.G. McKerron, R.L. Souhami, D.J.E. Taylor & H. Andrews, 1967. Severe systemic infections complicating ‘mainline’ heroin addiction. Lancet ii: 1227–1231.
Brown, S.M., B. Stimmel, R.N. Taub, S. Kochwa & R.E. Rosenfield, 1974. Immunologic dysfunction in heroin addicts. Arch. Intern. Med. 134: 1001–1006.
Brudney, K. & J. Dobkin, 1991. Resurgent tuberculosis in New York City. Am. Rev. Respir. Dis. 144: 744–749.
Buchbinder, S.P., M.H. Katz, N.A. Hessol, P.M. O'Malley & S.D. Holmberg, 1994. Long-term HIV-1 infection without immunologic progression. AIDS 8(8): 1123–1128.
Bureau of Justice Statistics, 1988. Special Report — Drug Law Violators, 1980–1986. U.S. Department of Justice, Washington, DC.
Bureau of Justice Statistics, 1991. Catalog of Federal Publications on Illegal Drug and Alcohol Abuse. U.S. Department of Justice, Washington, DC.
Burcau of Justice Statistics, 1992. Drugs, crime, and the justice system, U.S. Dept. of Justice, Washington, DC.
Cairns, J., 1978. Cancer: Science and Society. W.H. Freeman and Company, San Francisco.
Cairns, J., 1997. Matters of Life and Death; perspectives on public health, molecular biology, cancer, and the prospects for the human race. Princeton University Press, Princeton, New Jersey.
Callen, M., 1990. Surviving AIDS. HarperPerennial, New York.
Carman, J., 1998. ‘Frontline’ asks if drug war is going to pot. San Francisco Chronicle, April 28, p. E1.
Centers for Disease Control, 1981. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men — New York City and California. Morbidity and Mortality Weekly Reports 30: 305–308.
Centers for Disease Control, 1982. Update on acquired immune deficiency syndrome (AIDS) — United States. Morbid. Mortal. Weekly Rep. 31: 507–514.
Centers for Disease Control, 1983. An Evaluation of the Immunotoxic Potential of Isobutyl Nitrite. Morbid. Mortal Weekly Rep. 32(September 9): 457–458, 464.
Centers for Disease Control, 1985. Revision of the case definition of AIDS for national reporting — United States. Morb. Mortal. Weekly Rep. 34: 373–375.
Centers for Disease Control (eds), 1986. Reports on AIDS published in the Morbidity and Mortality Weekly Report, June 1981 through February 1986. U.S. Dept. of Health and Human Services, National Technical Information Service, Springfield, VA.
Centers for Disease Control, 1987. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. J. Am. Med. Assoc. 258: 1143–1154.
Centers for Disease Control, 1994. Hetereosexually acquired AIDS —United States, 1993. Morb. Mortal. Weekly Rep. 43(9): 155–160.
Centers for Disease Control, 1995. National HIV serosurveillance summary; update 1993. US Dept. HHS.
Centers for Disease Control and Prevention, 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb. Mort. Weekly Rep. 41(No.RR17): 1–19.
Centers for Disease Control and Prevention, 1995. U.S. HIV and AIDS cases reported through December 1995. HIV/AIDS Surveillance Report 7(2): 1–39.
Centers for Disease Control and Prevention, 1996. U.S. HIV and AIDS cases reported through December 1996. HIV/AIDS Surveillance Report 8(2): 1–39.
Centers for Discase Control and Prevention, 1997. U.S. HIV and AIDS cases reported through December 1997; Year-end edition. 9:(2) 1–43.
Chamberland, M. E., & J. W. Curran, 1990. Epidemiology and prevention of AIDS and HIV infection, pp. 1029–1046 in Principles and practice of infectious diseases edited by G.L. Mandel, R.G. Douglas & J.E. Benett, Churchill Livingstone, New York, Edinburgh, London.
Chiu, D. & P. Duesberg, 1995. The Toxicity of Aziodothymidine (AZT) on Human and Animal Cells in Culture at Concentrations Used for Antiviral Therapy. Genetica 95: 103–109.
Chorba, T.L., R.C. Holman, T.W. Strine, M.J. Clarke & B.L. Evatt, 1994. Changes in longevity and causes of death among persons with hemophilia A. Am. J. Hematol. 45: 112–121.
Clinton, W. & The White House, 1996. The National Drug Control Strategy: 1996. The White House, Washington, DC.
Cohen, J., 1993. HHS: Gallo guilty of misconduct. Science 259: 168–170.
Cohen, J., 1994a. The Duesberg Phenomenon. Science 266: 1642–1649.
Cohen, J., 1994b. Is a new virus the cause of KS? Science 266: 1803–1804.
Cohen, J., 1995. Researchers air alternative views on how HIV kills cells. Science 269(25 August): 1044–1045.
Cohen, J., 1997a. Advances painted in shades of gray at a D.C. conference. Science 275: 615–616.
Cohen, J., 1997b. The media's love affair with AIDS research: Hope vs. hype. Science 275: 298–299.
Cohen, S.S., 1987. Antiretroviral therapy for AIDS. N. Engl. J. Med. 317: 629.
Connor, E.M., R.S. Sperling, R. Gelber et al., 1994. Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 With Zidovudine Treatment. New Engl. J. Med. 331(18): 1173–1180.
Cotton, P., 1994. Trial Halted After Drug Cuts Maternal HIV Transmission Rate By Two Thirds. J. Am. Med. Assoc. 271(11): 807.
Courtwright, D.T., 1982. Dark Paradisc: opiate addiction in America before 1940. Harvard University Press, Cambridge, MA.
Craddock, M., 1996. A critical appraisal of the Vancouver men's study; does it refute the drugs/AIDS hypothesis? pp. 105–110 in AIDS: Virus or drug-induced edited by P.H. Duesberg. Kluwer Academic Publishers, Dordrecht, Netherlands.
Cronkite, E.P. & J. Bullis, 1990. In vivo toxicity of 3′-azido-2′,3′-dideoxythymidine (AZT) on CBA/Ca mice. International Journal of Cell Cloning 8: 332–345.
Culver, K.W., A.J. Ammann, J.C. Patridge, D.F. Wong, D.W. Wara & M.J. Cowan, 1987. Lymphocyte abnormalities in infants born to drug-abusing mothers. J. Pediatr. 111: 230–235.
Curran, J.W., M.W. Morgan, A.M. Hardy, H.W. Jaffe, W.W. Darrow & W.R. Dowdle, 1985. The epidemiology of AIDS: current status and future prospects. Science 229: 1352–1357.
Dalakas, M.C., I. Illa, G.H. Pezeshkpour, J.P. Laukaitis, B. Cohen & J.L. Griffin, 1990. Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med. 322: 1098–1105.
Darby, S.C., D.W. Ewart, P.L.F. Giangrande, P.J. Dolin, R.J.D. Spooner, C.R. Rizza & on behalf of the UK Haemophilia Centre Directors' Organisation, 1995. Mortality before and after HIV infection in the complete UK population of haemophiliaes (letter). Nature (London) 377(7 September): 79–82.
Darrow, W.W., D.F. Echenberg, H.W. Jaffe, P.M. O'Malley, R.H. Byers, J.P. Getchell & J.W. Curran, 1987. Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am. J. Publ. Health 77: 479–483.
Dax, E.M., J.E. Nagel, W.R. Lange, W.H. Adler & J.H. Jaffe, 1988. Effects of nitrites on the immune system of humans. pp. 75–59 in Health hazards of nitrite inhalants, NIDA Res. Monograph 83, edited by H.W. Haverkos & J.A. Dougherty. Dept. Health & Human Services, Washington, DC.
Des Jarlais, D., S. Friedman, M. Marmor et al., 1987. Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users. AIDS 1: 105–111.
Des Jarlais, D.C., S.R. Friedman & W. Hopkins, 1988. Risk reduction of the acquired immunodeficiency syndrome among intravenous drug users, pp. 97–109 in AIDS and IV Drug Abusers: Current Perspectives, edited by R.P. Galea, B.F. Lewis & L. Baker. National Health Publishing, Owings Mills, MD, USA.
Deutsche Hauptstelle gegen die Suchtgefahren, 1996. Jahrbuch Such '97. Neuland Verlag, Geesthacht, Germany.
Dismukes, W. E., A. W. Karchmer, R. F. Johnson & W. J. Dougherty, 1968. Viral hepatitis associated with illcit parenteral use of drugs. J. Am. Med. Assoc. 206: 1048–1052.
Donahoe, R.M., C. Bueso-Ramos, F. Donahoe, J.J. Madden, A. Falek, J.K.A. Nicholson & P. Bokos, 1987. Mechanistic implications of the findings that opiates and other drugs of abuse moderate T-cell surface receptors and antigenic markers. Ann. N.Y. Acad. Sci. 496: 711–721.
Douglas, R.G.J., 1990. Antimicrobial Agents, p. 1182 in The Pharmacological Basis of Therapeutics, edited by Alfred & Goodman & Gilman et al. Pergamon Press, New York.
Drotman, D.P. & H. Haverkos, 1992. What Causes Kaposi's Sarcoma? Inquiring Epidemiologists Want to Know. Epidemiology 3(3): 191–193.
Drotman, D.P., T.A. Peterman & A.E. Friedman-Kien, 1995. Kaposi's sarcoma. How can epidemiology help find the cause? Dermatoepidemiology 13(3): 575–582.
Drug Strategies, 1995. Keeping score; What We Are Getting for Our Federal Drug Control Dollars. Drug Strategies, Washington, DC.
Drug Strategies, 1996. Keeping Score, p. 1–33.
Duesberg, P.H., 1987. Retroviruses as carcinogens and pathogens: expectations and reality. Cancer Res. 47: 1199–1220.
Duesberg, P.H., 1988. HIV is not the cause of AIDS. Science 241: 514–516.
Duesberg, P.H., 1989. Human immunodeficiency virus and acquired immunodeficiency syndrome: Correlation but not causation. Proc. Natl. Acad. Sci. USA 86: 755–764.
Duesberg, P.H., 1991. AIDS epidemiology: inconsistencies with human immunodeficiency virus and with infectious disease. Proc. Natl. Acad. Sci. USA 88(Feb.): 1575–1579.
Duesberg, P.H., 1992a. AIDS acquired by drug consumption and other noncontagious risk factors. Pharmacology & Therapeutics 55: 201–277.
Duesberg, P.H., 1992b, HIV, AIDS, and zidovudine. Lancet 339: 805–806.
Duesberg, P.H., 1993a. Aetiology of AIDS. Lancet 341: 1544.
Duesberg, P.H., 1993b. Can epidemiology determine whether drugs or HIV cause AIDS? AIDS-Forschung 12: 627–635.
Duesberg, P.H., 1993c. HIV and AIDS. Science 260: 1705.
Duesberg, P.H., 1993d. HIV and the aetiology of AIDS. Lancet 341: 957–958.
Duesberg, P.H., 1993e. The HIV gap in national AIDS statistics. Biotechnology 11: 955–956.
Duesberg, P.H., 1994. Infectious AIDS — stretching the germ theory beyond its limits. Int. Arch. Allergy Immunol. 103: 131–142.
Duesberg, P.H., 1995a. AIDS Data. Science 268(21 April): 350–351.
Duesberg, P.H., 1995b. ‘The Duesberg-Phenomenon’: Duesberg and Other Voices (letter). Science 267: 313.
Duesberg, P.H., 1995c. Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV. Genetica 95: 51–70.
Duesberg, P.H., 1995d. Is HIV the cause of AIDS? (letter). Lancet 346(November 18): 1371–1372.
Duesberg, P.H., 1996a. Commentary: non-HIV hypotheses must be studied more carefully. Br. Med. J. 312(27 January): 210–211.
Duesberg, P.H., 1996b. Duesberg's questions. C&EN (March 25) 4, 40.
Duesberg, P.H., 1996c. How much longer can we afford the AIDS virus monopoly? pp. 241–270 in AIDS: virus-or drug induced?, edited by P. Duesberg. Kluwer, Dordrecht, Netherlands.
Duesberg, P.H., 1996d. Inventing the AIDS Virus. Regnery Publishing Inc., Washington.
Duesberg, P.H., & H. Bialy, 1996. Duesberg and the right of reply according to Maddox-Nature. pp. 111–125 in AIDS: virus-or Drug-Induced?, 5, edited by P. H. Duesberg. Kluwer Academic Publishers, Dordrecht/Boston/London.
Duesberg, P.H., & D. Rasnick, 1997. The drug AIDS hypothesis. Continuum (London) 4Supplement (5): 1–24.
Durack, D.T., 1981. Opportunistic infections and Kaposi's sarcoma in homosexual men. The New England Journal of Medicine 305(24): 1465–1467.
Ellison, B. J., A. B. Downey & P. H. Duesberg, 1996. HIV as a surrogate marker for drug-use: a re-analysis of the San Francisco Men's Health Study. pp. 97–194 in AIDS: virus-or drug induced?, edited by P.H. Duesberg. Kluwer Academic Publishers, Dordrecht, The Netherlands.
Espinoza, P., I. Bouchard, C. Buffet, V. Thiers, J. Pillot & J.P. Etienne, 1987. High prevalence of infection by hepatitis B virus and HIV in incarcerated French drug addicts. Gastroenterologie Clinique et Biologique 11(4): 288–292.
Ettinger, N.A., & R.J. Albin, 1989. A review of the respiratory effects of smoking cocaine. Am. J. Med. 87: 664–668.
European Collaborative Study, 1991. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 337: 253–260.
Evans, A.S. (eds), 1982. Viral Infection of Humans: Epidemiology and Control. Plenum Medical Book Company, New York/London.
Evans, A.S. & H.A. Feldman (eds), 1982. Bacterial Infections of Humans: epidemiology and Control. Plenum Medical Book Company, New York/London.
Evenson, L. & S. Whiting, 1996. Heroin's in Fashion — and Death Statistics Prove It. San Francisco Chronicle, Jul 30, p A1–A8.
Farber, C., 1994. AIDS: Words from the Front. SPIN, April, p. 81–83, 102.
Fenner, F., B.R. McAuslan, C.A. Mims, J. Sambrook & D.O. White, 1974. The Biology of Animal Viruses. Academic Press, Inc., New York.
Fettner, A.G. & W.A. Check, 1985. The Truth about AIDS: Evolution of an Epidemic. Holt, Rinehart and Wilson, New York.
Fiala, C., 1998. AIDS in Africa: dirty tricks. New African, p. 36–38.
Fiala, C. & P.M. Lingens, 1997. Leben wir gefaehrlich? F. Deuticke Verlagsgesellschaft, Wien, Austria.
Fietz, M., 1997. Haschisch an der Spitze; SPD: Mildere Strafen fuer Drogenhaendler. Die Welt, Jan. 8, p. 1,2.
Fineberg, H. V., 1988. The social dimensions of AIDS. Sci. Am., p. 128–134.
Finnegan, L.P., J.M. Mellot, L.R. Williams & R.J. Wapner, 1992. Perinatal exposure to cocaine: Human studies. pp. 391–409 in Cocaine: Pharmacology, Physiology and Clinical Strategies edited by J.M. Lakoski, M.P. Galloway & F.J. White. CRC Press. Boca Raton, FL.
Firooznia, H., G. Seliger & R. M. Abrams, 1973. Disseminated extrapulmonary tuberculosis in association with heroin addiction. Radiology 109: 291–296.
Fischl, M.A., D.D. Richman, D. M. Causey et al., 1989. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. J. Am. Med. Assoc. 262(17): 2405–2410.
Fischl, M.A., D.D. Richman, M.H. Grieco et al., 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317: 185–191.
Flanagan, T. J. & K. Maguire, 1989. Sourcebook of Criminal Justice Statistics (1989) — Bureau of Justice Statistics NCJ-124224. U.S. Department of Justice, U.S. Government Printing Office, Washington, DC, USA.
Fogelman, I., L. Lim, R. Bassett, P. Volberding, M.A. Fischl, K. Stanley, D.J. Cotton & for the AIDS Clinical Trials Group, 1994. Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type 1 clinical trials. Journal of Acquired Immune Deficiency Syndromes 7: 1057–1063.
Francis, D. P., J. W. Curran & M. Essex, 1983. Epidemic acquired immune deficiency syndrome: Epidemiologic evidence for a transmissible agent. J. Natl. Cancer Inst. 71:(1) 1–4.
Freeman, E., 1996. HIV does not cause AIDS. Health Quest, Fall 1996, p. 35–49.
Freestone, D.S., 1992. Zidovudine. Lancet 339: 626.
Freiman, J.P., K.E. Helfert, M.R. Hamrell & D.S. Stein, 1993. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 7: 379–385.
Fricker, H.S. & S. Segal, 1978. Narcotic addiction, pregnancy, and the newborn. Am. J. Dis. Child. 132: 360–366.
Friedman, L.N., M.T. Williams, T.P. Singh & T.R. Frieden, 1996. Tuberculosis, AIDS, and death among substance abusers on Welfare in New York City. N. Engl. J. Med. 334(13): 828–833.
Friedman-Kien, A.E., B.R. Saltzman, Y. Cao, M.S. Nestor, M. Mirabile, J.J. Li & T.A. Peterman, 1990. Kaposi's sarcoma in HIV-negative homosexual men. Lancet 335: 168–169.
Gallagher, J., 1997. Slipping up; unsafe sex is on the rise — and the new AIDS drugs are only one of the culprits. The Advocate, July 8, p. 33–34.
Gallo, R. C., 1991....and his response. Nature (London) 351: 358.
Gallo, R.C., S.Z. Salahuddin, M. Popovic et al., 1984. Frequent detection and isolation of cytopathic retrovirus (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500–503.
Gallo, R.C., P.S. Sarin, E.P. Gelmann, M. Robert-Guroff & E. Richardson, 1983. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220: 865–867.
Ganem, D., 1997. KSHV and Kaposi's sarcoma: the end of the beginning? Cell 91: 157–160.
Garay, S.M., M. Belenko, E. Fazzini & R. Schinella, 1987. Pulmonary manifestations of Kaposi's sarcoma. Chest 91: 39–43.
Garrett, L., 1998. Weird symptoms seen with new AIDS drugs. San Francisco Chronicle, February 5, p. A7.
Geller, S.A. & B. Stimmel, 1973. Diagnostic confusion from lymphatic lesions in heroin addicts. Ann. Intern. Med. 78: 703–705.
Gibbons, J., 1996. Drugs & Us. Gay Times (London), September, p. 17–37.
Gill, P.S., B. Akli, P. Coletti, M. Rarick, C. Louriero, M. Bernstein-Singer, M. Krailo & L.A.M., 1989. Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. Am. J. Med. 87: 57–61.
Gill, P.S., M. Rarick, R.K. Byrnes, D. Causey, C. Loureiro & A.M. Levinc, 1987. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 107: 502–505.
Goedert, J.J., A.R. Cohen, C.M. Kessler, S. Eichinger, S.V. Seremetis, C.S. Rabkin, F.J. Yellin, P.S. Rosenberg & L.M. Aledort, 1994. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Lancet 344: 791–792.
Goedert, J.J., C.Y. Neuland, W.C. Wallen, M.H. Greene, D.L. Mann, C. Murray, D.M. Strong, J.F. Fraumeni, Jr. & W.A. Blattner, 1982. Amyl nitrite may alter T lymphocytes in homosexual men. Lancet i: 412–416.
Gorard, D.A. & R.J. Guilodd, 1988. Necrotising myopathy and zidovudine. Lancet i: 1050.
Gottlieb, M.S., H.M. Schanker, P.T. Fan, A. Saxon, J.D. Weisman & J. Pozalski, 1981a. Pneumocystis pneumonia — Los Angeles. Morbidity and Mortality Weekly Reports 30: 250–252.
Gottlieb, M.S., R. Schroff, H.M. Schanker, J.D. Weisman, P.T. Fan, R.A. Wolf & A. Saxon, 1981b. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305: 1425–1431.
Grcenblatt, R.M., H. Hollander, J.R. McMaster & C.J. Henke, 1991. Polypharmacy among patients attending an AIDS clinic: utilization of prescribed, unorthodox, and investigational treatments. Journal of Acquired Immune Deficiency Syndromes 4(2): 136–143.
Grossman, S.J., N. Reinfoed, R.S. Eydelloth, D.W. Alberts, P.F. Smith & D.H. Patrick, 1997. Hepatotoxicity of an HIV protease inhibitor in dogs and rats. Toxicol. Appl. Pharmacol. 146(1): 40–52.
Grubman, S., E. Gross, N. Lerner-Weiss, M. Hernandez, G.D. McSherry, L.G. Hoyt, M. Boland & J.M. Oleske, 1995. Older Children and Adolescents Living with Perinatally Acquired Human Immunodeficiency Virus Infection. Pediatrics 95(5): 657–663.
Gutknecht, G., 1995. Letter of Congressman Gil Gutknecht to Dr. Anthony Fauci, director of the National Institute of Allergies and Infectious Diseases, in Inventing The AIDS Virus by Peter Duesberg, A. Regnery, Washington, DC, 1996.
Hall, C.T., 1996. AIDS advances boost drugmaker. San Francisco Chronicle, August 1, p. E1–E2.
Hallauer, J. F. & S. Kupsch, 1997. Die HIV/AIDS-Pandemie. pp. 1–32, in AIDS und die Vorstadien edited by J. L'age-Stehr & E.B. Helm. Springer Verlag, Berlin, Heidelberg.
Harden, V.A., 1992. Koch's postulates and the etiology of AIDS: an historical perspective. Hist. Phil. Life Sci. 14: 249–269.
Harris, P.D. & R. Garret, 1972. Susceptibility of addicts to infection and neoplasia. New. Engl. J. Med. 287: 310.
Haverkos, H. W., 1988. Kaposi's sarcoma and nitrite inhalants, pp. 165–172 in Psychological, Neuropsychiatric and Substance Abuse Aspects of AIDS, edited by T.P. Bridge, H. Heather & M. Johnson, Raven Press, New York.
Haverkos, H.W., 1990. Nitrite inhalant abuse and AIDS-related Kaposi's sarcoma. J. Acquir. Immune Defic. Syndr. 3:Supplement 1, S47–S50.
Haverkos, H.W. & J. Dougherty, 1988a. Health hazards of nitrite inhalants. Am. J. Med. 84: 479–482.
Haverkos, H.W. & J.A. Dougherty (eds), 1988b. Health Hazards of Nitrite Inhalants. 83, US. Dept. Health & Human Services, Washington, DC.
Haverkos, H.W. & D.P. Drotman, 1995. NIDA Technical Review: Nitrite Inhalants. NIDA, Washington, DC & CDC, Atlanta, GA, unpublished.
Haverkos, H.W., D.P. Drotman & D. Hanson, 1994. Surveillance for AIDS-related Kaposi's sarcoma (KS): update. NIDA/CDC, Rockville, MD/Atlanta, GA, May.
Haverkos, H.W., P.F. Pinsky, D.P. Drotman & D.J. Bregman, 1985. Disease manifestation among homosexual men with acquired immunodeficiency syndrome: a possible role of nitrites in Kaposi's sarcoma. J. Sex. Trans. Dis. 12: 203–208.
Hayes, T., R. Altman, A. Akili-Obika, J.W. Buehler, S.J. Costa, J.K. Beil, L.G. Moore, J.W. Massey & N.M. Williams, 1994. HIV-related deaths from selected infectious diseases among persons without AIDS in New Jersey. Journal of Acquired Immune Deficiency Syndromes 7: 1074–1078.
Heitz, D., 1997. Men behaving badly; the recklessness of the 1970s and early '80s has reappeared on the party circuit, where gay men are indulging in illicit drugs and wild sex with increasing abandon. The Advocate, July 8, p. 26–29.
Helbert, M., T. Fletcher, B. Peddle, J.R.W. Harris & A.J. Pinching, 1988. Zidovudine-associated myopathy. Lancet ii: 689–690.
Heresi, G.P., E. Caceres, J.T. Atkins, J. Rueben & M. Doyle, 1997. Pneumocystis carinii pneumonia in infants who were exposed to human immunodeficiency virus but were not infected: an exception to the AIDS Surveillance case definition. Clinical Infectious diseases 25: 739–740.
Hitchcock, M.J.M., 1991. Review: Antiviral portrait series, Number 1; 2′,3′-Didehydro-2′,3′-dideoxythymidine (D4T), an anti-HIV agent. Antiviral Chem. Chemother. 2(3): 125–132.
Hodgkinson, N., 1996. AIDS: the failure of contemporary science. Fourth Estate, London, UK.
Holding, R. & W. Carlsen, 1998. Epidemic ravages caregivers. San Francisco Chronicle, 13 April, p. 1,A6–A8.
Holtermann, S., 1997. Glueck aus der Pille? First, May, p. 16–17.
Horton, R., 1995. Will Duesberg now concede defeat? Lancet 346: 656.
Horwitz, J.P., J. Chua & M. Noel, 1964. Nucleosides. V. The monomesylates of 1-(2′-deoxy-beta-D-lyxofuranosyl)thymidine. J. Org. Chem. 29: 2076.
Hudson, R. & S. Davidson, 1986. Rock Hudson — his story. William Morrow & Co., New York.
Hughes, M.D., D.S. Stein, H.M. Gundacker, F.T. Valentine, J.P. Phair & P.A. Volberding, 1994. Within-Subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: Implications for patient Monitoring. J. Infectious Diseases 169: (January) 28–36.
Ineichen, H., 1996. Ausgeschnüffelt? aK (Switzerland), October November, p. 18–19.
Inoue, T., E.P. Cronkite, Y. Hirabayashi, J.E. Bullis, H. Mitsui & T. Umemura, 1997. Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia. Leukemia 11: 123–127.
Institute of Medicine & National Academy of Sciences, 1986. Confronting AIDS. National Academy Press, Washington, DC.
Irwin, D.H. & L.D. Kaplan, 1993. Pulmonary manifestations of acquired immunodeficiency syndrome-associated malignancies. Seminars in Respiratory Infections 8: 139–148.
Jacobson, M.A., P. de Miranda, S.M. Gordon, M.R. Blum, P. Volberding & J. Mills, 1988. Prolonged pancytopenia due to combined ganciclovir and zidovuduine therapy. J. Infect. Dis. 158: 489–490.
Jacquez, J.A., J.S. Koopman, C.P. Simon & I.M. Longini Jr., 1994. Role of the primary infection in epidemies of HIV infection in gay cohorts. J. Acquired Immune Deficiency Syndromes 7(11): 1169–1184.
Jaffe, H.W., K. Choi, P.A. Thomas et al., 1983. National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: Part 1, Epidemiologic results. Ann. Intern. Med. 99(2): 145–151.
Jonnes, J., 1996. Hep-cats, nares, and pipe dreams. Seribner, New York.
Kaposi, M., 1872. Idiopathisches multiples Pigmentsarkom der Haut. Archiv für Dermatologie und Syphilis 2: 265–273.
Karpas, A., S. Ash & D. Bainbridge, 1997. Are anti-HIV drugs an effective treatment? Nature Medicine 3(10): 1052.
Kaslow, R.A., W.C. Blackwelder, D.G. Ostrow, D. Yerg, J. Palenicek, A.H. Coulson & R.O. Valdiserri, 1989. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. J. Am. Med. Assoc. 261: 3424–3429.
Klimas, N.G., N.T. Blaney, R.O. Morgan, D. Chitwood, K. Milles, H. Lee & M.A. Fletcher, 1991. Immune function and Anti-HTLV-I/II status in Anti-HIV-1-Negative intravenous drug users receiving methadone. The American Journal of Medicine 90 (February): 163–170.
Kline, M.W., R.B. Van Dyke, J.C. Lindsey et al., 1998. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDU, AZT) in children with human immunodeficiency virus infection. Pediatrics 101(2): 214–220.
Koch, T., 1990. Uninfected children of HIV-infected mothers may still suffer nervous problems. CDC AIDS Weekly, July 30, p. 9.
Kolata, G., 1987. Imminent marketing of AZT raises problems; Marrow suppression hampers AZT use in AIDS victims. Science 235: 1462–1463.
Kolata, G., 1995. New picture of who will get AIDS is dominated by addicts. New York Times, February 28, p. 3, Sect. C.
Kozel, N.J. & E.H. Adams, 1986. Epidemiology of drug abuse: An overview. Science 234: 970–974.
Kramer, L., 1994. Checking in, my chart. POZ, August/September, p. 92–93.
Kramer, L., 1996. A good news/bad news AIDS joke. New York Times, Sunday, July 14, p. 26.
Krieger, L., 1996. 1 in 300 U.S. adults infected, says report. San Francisco Examiner, July 7, p. A8.
Krieger, L.M., 1997. AIDS drug cocktails fail 53% in study. San Francisco Examiner, September 29, p. 1, A10.
Krieger, T. & C.A. Caceres, 1985. Wall Street Journal, October 24, p.
Kumar, R.M., P.F. Hughes & A. Khurranna, 1994. Zidovudine Use in Pregnancy: A Report on 104 Cases and the Occurence of Birth Defects. Journal of Acquired Immune Deficiency Syndromes 7(10): 1034–1039.
Lang, S., 1996. To fund or not to fund, that is the question: proposed experiments on the drug-AIDS hypothesis. To inform or not to inform, that is another question, pp. 297–307 in AIDS: Virus or Drug-Induced?, edited by P.H. Duesberg. Kluwer, Dordrecht, The Netherlands.
Lang, S., 1998. Challenges. Springer, New York.
Larrat, P.E. & S. Zierler, 1993. Entangled epidemies: cocaine use and HIV disease. J Psychoactive drugs 25(3): 207–221.
Lauritsen, J., 1990. Poison by Prescription — The AZT Story. Asklepios Press, New York.
Lauritsen, J., 1992. FDA documents show fraud in AZT trials. New York Native, March 30, p. 20–23.
Lauritsen, J., 1993. The AIDS War. Asklepios (Pagan Press), New York.
Lauritsen, J., 1994. NIH reconsiders nitrites' link to AIDS. Biotechnology 12: 762–763.
Lauritsen, J., 1996. NIDA meeting calls for research into the poppers-Kaposi's sarcoma connection, pp. 325–330 in: AIDS: Virus or Drug-Induced?, edited by P.H. Duesberg. Kluwer Academic Publishers, Dordrecht, The Netherlands.
Lauritsen, J. & H. Wilson, 1986. Death Rush, Poppers and AIDS. Pagan Press, New York.
Lauritsen, J. & I. Young, 1997. The AIDS Cult; essays on the Gay Health Crisis. Asklepios-Pagan Press, Provincetown, MA.
Layon, J., A. Idris, M. Warzynski, R. Sherer, D. Brauner, O. Patch, D. McCulley & P. Orris, 1984. Altered T-lymphocyte subsets in hospitalized intravenous drug abusers. Arch. Intern. Med. 144: 1376–1380.
Lazarou, J., B.H. Pomeranz & P.N. Corey, 1998. Incidence of adverse drug reactions in hospitalized patients. Journal of American Medical Association 279: 863–867.
Learmont, J., B. Tindall, L. Evans, A. Cunningham, P. Cunningham, J. Wells, R. Penny, J. Kaldor & D. A. Cooper, 1992. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 340: 863–867.
Leland, J., 1996. The end of AIDS? Newsweek, December 2, p. 64–73.
Lerner, W.D., 1989. Cocaine abuse and acquired immunodeficiency syndrome: tale of two epidemics. Am. J. Med. 87: 661–663.
Levy, J., 1998. Caution: should we be treating HIV infection early? Lancet 352: 982–983.
Lifschitz, M.H., G.S. Wilson, E.O. Smith & M.M. Desmond, 1983. Fetal and postnatal growth of children born to narcotic-dependent women. J. Pediatr. 102: 686–691.
Lifson, A.R., W.W. Darrow, N.A. Hessol, P.M. O'Malley, J.L. Barnhart, H.W. Jaffe & G.W. Rutherford, 1990. Kaposi's sarcoma in a cohort of homosexual and bisexual men: epidemiology and analysis for cofactors. Am. J. Epidemiol. 131: 221–231.
Lipsky, J.J., 1998. Abnormal fat accumulation in patients with HIV-1 infection. Lancet 351: 847–848.
Lo, J.C.K., 1998. ‘Buffalo hump’ in men with HIV-1 infection. Lancet 351: 867–870.
Lockemann, U., F. Wischhusen, K. Pueschel & (over 20 authors), 1995. Vergleich der HIV-1-Praevalenz bei Drogentodesfaelien in Deutschland sowie in verschiedenen europaeischen Grosstaedten (Stand: 31. 12. 1993). AIDS Forschung 10: 253–256.
Los Angeles Times, 1998. Clinton to announce new drug plan. San Francisco Chronicle, February 13, p. A17.
Louria, D.B., 1974. Infectious complications of nonalcoholic drug abuse. Annu. Rev. Med. 25: 219–231.
Luzuriaga, K., Y. Bryson, P. Krogstad, J. Robinson, B. Stechenberg, M. Lamson, S. Cort & J.L. Sullivan, 1997. Combination treatment with zidovudine, didiadenosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N. Engl. J. Med. 336: 1343–9.
Lyles, C.M., J.B. Margolick, J. Astemborski, N.M. Graham, J.C. Anthony, D.R. Hoover & D. Vlahov, 1997. The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users, AIDS 11(10): 1255–1262.
Maddox, J., 1992. Rage and confusion hide role of HIV. Nature (London) 357: 188–189.
Maddox, J., 1993. Has Duesberg a right of reply? Nature (London) 363: 109.
Maddox, J., 1995. More conviction on HIV and AIDS. Nature (London) 377: 1.
Mann, C., 1995. Poppers... high time to think again. Continuum (London, UK) 3(3): 10.
Mann, J., J. Chin, P. Piot & T. Quinn, 1988. The international epidemiology of AIDS. Sci. Am., p. 82–89.
Marmor, M., A.E. Friedman-Kien, L. Laubenstein, R.D. Byrum, D.C. William, S. D'Onofrio & N. Dubin, 1982. Risk factors for Kaposi's sarcoma in homosexual men. Lancet i: 1083–1087.
Marquart, K.-H., R. Engst & G. Oehlschlaegel, 1991. An 8-year history of Kaposi's sarcoma in an HIV-negative bisexual man. AIDS 5(3): 346–348.
Martinez, M., 1997. The existence of human immunodeficiency virus resistance to nucleoside-analog drugs has not been shown. Med. Hypotheses 49: 235–240.
Mathur-Wagh, U., R.W. Enlow, I. Spigland et al., 1984. Longitudinal study of persistent generalized lymphadenopathy in homosexual men: Relation to acquired immunodeficiency syndrome. Lancet i: 1033–1038.
Mathur-Wagh, U., D. Mildvan & R.T. Senie, 1985. Follow-up of 4 1/2 years on homosexual men with generalized lymphadenopathy. N. Engl. J. Med. 313: 1542–1543.
Maugh II, T.H., 1998. Researchers on path to first inexpensive AIDS medication. San Francisco Chronicle, February 6, p. A6.
McDonough, R.J., J.J. Madden, A. Falek, D.A. Shafer, M. Pline, D. Gordon, P. Bokof, J.C. Kuehnle & J. Mandelson, 1980. Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence of opiate receptor sites on T lymphocytes. J. Immunol. 125: 2539–2543.
McEvoy, A. W., N.D. Kitchen & D.G.T. Thomas, 1998. Intracerebral haemorrhage caused by drug abuse. Lancet 351: 1029.
McLeod, G.X. & S.M. Hammer, 1992. Zidovudine: Five years later. Ann. Intern. Med. 117(6): 487–501.
McManus, T.J., L.A. Starrett & J.R.W. Harris, 1982. Amyl Nitrite use by homosexuals. Lancet i (February 27): 503.
Meduri, G.U., D.E. Stover, M. Lee, P.L. Myskowski, J.F. Caravelli & M.B. Zama, 1986. Pulmonary Kaposi's sarcoma in the acquired immune deficiency syndrome: clinical, radiographic, and pathologic manifestations. Am. J. Med. 81: 11–18.
Merck & Co., 1997. Crixivan (Indinavir sulfate): patient information about Crixivan. SPIN, June, 1997, p111–114.
Merck Research Laboratories, 1992. The Merck Manual of Diagnosis and Therapy. Merck & Co., Inc., Rahway, NJ.
Merriam-Webster (eds), 1965. Webster's Third International Dictionary. G. & C. Merriam Co., Springfield, MA.
Merson, M.H., 1993. Slowing the spread of HIV: Agenda for the 1990s. Science 260: 1266–1268.
Mientjes, G.H., F. Miedema, E.J. van Ameijden, A.A. van den Hoek, P.T.A. Schellekens, M.T. Roos & R.A. Coutinho, 1991. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS 5: 35–41.
Mientjes, G.H.C., E.J.C. van Ameijden, H.M. Weigel, J.A.R. van den Hoek & R.A. Countinho, 1993. Clinical symptoms associated with seroconversion for HIV-1 among misusers of intravenous drugs: comparison with homosexual seroconverters and infected and non-infected intravenous drug misusers. Br. Med. J 306: 371–373.
Miller, K.D., E. Jones, J.A. Yanovski, R. Shankar, I. Feuerstein & J. Falloon, 1998. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351: 871–875.
Mills, J. & H. Masur, 1990. AIDS-related infections. Sci. Am. 263(2): 50–57.
Mims, C. & D.O. White, 1984. Viral Pathogenesis and Immunology. Blackwell Scientific Publications, Oxford.
Mirken, B., 1995. Everything you always wanted to know about poppers; the ‘gay drug’ is still here despite a ban, and so is the controversy. San Francisco Frontiers Newsmagazine, July 20, p. 16–19.
Moberg, C.L. & Z.A. Cohn, 1991. Rene Jules Dubos. Sci. Am. 264(5): 66–74.
Mok, J.Q., A. De Rossi, A.E. Ades, C. Giaquinto, I. Grosch-Woerner & C.S. Peckham, 1987. Infants born to mothers seropositive for human immunodeficiency virus. Lancet i: 1164–1168.
Moss, A.R., 1987. AIDS and intravenous drug use: the real heterosexual epidemic. Br. Med. J. 294: 389–390.
Moye, J., K.C. Rich, L.A. Kalish, A.R. Sheon, C. Diaz, E.R. Cooper, J. Pitt, E. Handelsman & for the Women and Infants Transmission Study Group, 1996. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. The Journal of Pediatrics 128(1): 58–67.
Mullis, K., 1996. Foreword, pp. XI–XIV in Inventing the AIDS Virus, edited by P. Duesberg. Regnery Publishing, Inc., Washington, DC.
Mullis, K.B., 1995. A hypothetical disease of the immune system that may bear some relation to the Acquired Immune Deficiency Syndrome. Genetica 95(1–3): 195–197.
Muñoz, A., D. Vlahov, L. Solomon, J.B. Margolick, J.C. Bareta, S. Cohn, J. Astemborski & K.E. Nelson, 1992. Prognostic indicators for development of AIDS among intranvenous drug users. J. Acquir. Immune Defic. Syndr. 5: 694–700.
Murray, H.W., D.A. Scavuzzo, C.D. Kelly, B.Y. Rubin & R.B. Roberts, 1988. T4+ cell production of interferon gamma and the clinical spectrum of patients at risk for and with acquired immunodeficiency syndrome. Arch. Intern. Med. 148: 1613–1616.
National Commission on AIDS, July 1991. The Twin Epidemics of Substance Use and HIV. National Commission on AIDS.
National Research Council, 1982. Diet, nutrition, and cancer. National Acad. Press, Washington, DC.
New York Times, 1997. Most $1 bills tainted by cocaine, lab finds. The New York Times, September 23.
Newell, G.R., S.C. Adamas, P.W.A. Mansell & E.M. Hersh, 1984. Toxicity, immunosupprressive effects, and carcinogenic potential of volatile nitrites: possible relationship to Kaposi's sarcoma. Pharmacotherapy 4: 284–291.
Newell, G.R., P.W.A. Mansell, M.R. Spitz, J.M. Reuben & E.M. Hersh, 1985a. Volatile nitrites: Use and adverse effects related to the current epidemic of the acquired immune deficiency syndrome. Am. J. Med. 78: 811–816.
Newell, G.R., P.W.A. Mansell, M.B. Wilson, H.K. Lynch, M.R. Spitz & E.M. Hersh, 1985b. Risk factor analysis among men referred for possible acquired immune deficiency syndrome. Preventive Med. 14: 81–91.
Nieman, R.B., J. Fleming, R.J. Coker, J.R. Harris & D.M. Mitchell, 1993. The effect of cigarette smoking on the development of AIDS in HIV-1-seropositive individuals. AIDS 7: 705–710.
Novick, D.M., M. Ochshorn, V. Ghali, T.S. Croxson, W.D. Mercer, N. Chiorazzi & M.J. Kreek, 1989. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadonc maintenance patients. The Journal of Pharmacology and Experimental Therapeutics 250(2): 606–610.
Nussbaum, B., 1990. Good Intentions: How Big Business, Politics, and Medicine are Corrupting the Fight Against AIDS. Atlantic Monthly Press, New York.
O'Brien, S.J., 1997. The HIV-AIDS debate is over. HIV Newsline 4: 3–9.
O'Brien, S.J. & J.J. Goedert, 1996. HIV causes AIDS: Koch's postulates fulfilled. Current Opinion in Immunology 8: 613–618.
Office of National Drug Control Policy, 1996. Drugs & Crime Data. Drugs & Crime Clearinghouse, July 1996.
Olivero, O.A., L.M. Anderson, B.A. Diwan et al., 1997. Transplacental effects of 3′-azido-2′, 3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J. Natl. Cancer Inst. 89: 1602–1608.
Omar, R.F., P. Gourde, A. Desormeaux, M. Tremblay, D. Beauchamp & M.G. Bergeron, 1996. In vivo toxicity of foscarnet and zidovudine given alone or in combination. Toxicol. Appl. Pharmacol. 139: 324–332.
Oppenheimer, G.M., 1992. Causes, cases, and cohorts: The role of epidemiology in the historical construction of AIDS, pp. 49–83 in AIDS: The Making of a Chronic Disease, edited by E. Fee & D.M. Fox. University of California Press, Berkeley, California.
Ostrow, D.G., 1994. Substance abuse and HIV infection. Psychiatric Manifestations of HIV Disease 17(1): 69–89.
Ostrow, D.G., E.D. Beltran, J.G. Joseph, W. DiFranceisco, J. Wesch & J.S. Chmiel, 1993. Recreational drugs and sexual behavior in the Chicago MACS/CCS cohort of homosexually active men. J. Subst. Abuse 5: 311–325.
Ostrow, D.G., M.J. Van Raden, R. Fox, L.A. Kingsley, J. Dudley, R.A. Kaslow & the Multicenter AIDS Cohort Study (MACS), 1990. Recreational drug use and sexual behavior change in a cohort of homosexual men. AIDS 4(8): 759–765.
Padian, N.S., S.C. Shiboski, S.O. Glass & E. Vittinghoff, 1997. Heterosexual transmission of human immunodeficiency virus (HIV) in Northern California: results from a ten-year study. Am. J. Epidemiol. 146: 350–357.
Parker, S.L., T. Tong, S. Bolden & P.A. Wingo, 1996. Cancer statistics, 1996. CA Cancer J Clin 46: 5–27.
Parker, W.B. & Y.C. Cheng, 1994. Mitochondrial Toxicity of Antiviral Nucleoside Analogs. The Journal of NIH Research 6 (March): 57–61.
Pellegrino, T. & B.M. Bayer, 1998. In vivo effects of cocaine on immune cell function. J Neuroimmunol 83(1–2): 139–147.
Pennisi, E. & J. Cohen, 1996. Eradicating HIV from a patient: not just a dream? Science 272: 1884.
Perlman, D., 1998. Quarter of AIDS patients not getting best therapy. San Francisco Chronicle, Thursday, June 4, 1998, p. A9.
Peterman, T.A., R.L. Stonebumer, J.R. Allen, H.W. Jaffe & J.W. Curran, 1988. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. J. Am. Med. Assoc. 259: 55–58.
Phillips, A.N. & G.D. Smith, 1997. Viral load and combination therapy for human immunodeficiency virus. N. Engl. J. Med. 336(13): 958–959.
Physician's Desk Reference, 1997. Invirase. In: M. E. Co. (eds.). Montvale, NJ.
Pillai, R., B.S. Nair & R.R. Watson, 1991. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch. Toxicol. 65: 609–617.
Pillari, G. & J. Narus, 1973. Physical effects of heroin addiction. Am. J. Nursing 73: 2105–2109.
Pink Paper, 1996. Shops on their guard after poppers sale legal setback. The Pink Paper, London, UK June 28
Pitot, H.C., 1986. Fundamentals of Oncology. Marcel Dekker, Inc., New York.
Pluda, J.M., R. Yarchoan, E.S. Jaffe et al., 1990. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann. Intern. Med. 113(4): 276–282.
Potts, M., 1995. Non-surgical abortion: who's for methotrexate. Lancet 346 (September 9): 655–656.
Poznansky, M.C., R. Coker, C. Skinner, A. Hill, S. Bailey, L. Whitaker, A. Renton & J. Weber, 1995. HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. Br. Med. J. 311: 156–158.
Race, E.M., J. Adelson-Mitty, G.R. Kriegel, T.F. Barlam, K.A. Reimann, N.L. Letvin & A.J. Japour, 1998. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 351 (January 24): 252–255.
Rappoport, J., 1988. AIDS INC. Human Energy Press, San Bruno, CA.
Ratajczak, H.V., P.T. Thomas, R.V. House et al., 1995. Local versus Systemic Immunotoxicity of Isobutyl Nitrite Following Subchronic Inhalation Exposure of Female B6C3F1 Micc. Fundamental and Applied Toxicology 27: 177–184.
Retrovir, 1994. Physicians' Desk Reference. Medical Economics Co., Orandell, NJ.
Richman, D.D., M.A. Fischl, M.H. Grieco et al., 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317: 192–197.
Rodriguez, E.M., L.M. Mofenson, B.-H. Chang et al., 1996. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 10: 273–282.
Roederer, M., 1998. Getting to the HAART of T cell dynamics. Nature Medicine 4(2): 145–146.
Rogers, M.F., C.-Y. Ou, M. Rayfield et al., 1989. Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. N. Engl. J. Med. 320: 1649–1654.
Root-Bernstein, R., 1993. The tragic cost of premature consensus. Free Press, New York, NY.
Rotello, G., 1996. A deal with the devil. The Advocate, October, 15, p. 96.
Russel, S., 1998. AIDS deaths drop 60% in California. San Francisco Chronicle, January 9, p. 1, A12.
Russell, S., 1996. "speed’ Hospitalizations Soar. San Francisco Chronicle, July 2, p. A13, A15.
Saah, A.J., D.R. Hoover, Y. Peng, J.P. Phair, B. Visscher, L.A. Kingsley, L.K. Schrager & for the Multicenter AIDS Cohort Study, 1995. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. J. Am. Med. Assoc. 273: 1197–1202.
Sabin, C.A., A.N. Phillips & C.A. Lee, 1996. Response: arguments contradict the ‘foreign protein-zidovudine’ hypothesis. Br. Med. J. 312: 211–212.
Sadownick, D., 1994. Kneeling at the Crystal Cathedral. Genre, December/January 1994, p. 40–45, 86–90.
Safai, B., H. Peralta, K. Menzies, H. Tizon, P. Roy, N. Flomberg & S. Wolinsky (1991) Kaposi's sarcoma among HIV-negative high risk population. VII International Conference on AIDS, Florence, Italy.
San Francisco Department of Public Health & Lesbian & Gay Substance Abuse Planning Group, 1991. Lesbian, Gay and Bisexual Substance Abuse Needs Assessment. San Francisco Department of Public Health.
Sapira, J.D., 1968. The narcotic addict as a medical patient. Am. J. Med. 45: 555–588.
Savona, S., M.A. Nardi, E.T. Lenette & S. Karpatkin, 1985. Thrombocytopenic purpura in narcotics addicts. Ann. Intern. Med. 102(6): 737–741.
Schechter, M.T., K.J.P. Craib, K.A. Gelmon, J.S.G. Montaner, T.N. Le & M.V. O'Shaughnessy, 1993a. HIV-1 and the aetiology of AIDS. Lancet 341: 658–659.
Schechter, M.T., K.J.P. Craib, K.A. Gelmon, J.S.G. Montaner, T.N. Le & M.V. O'Shaughnessy, 1993b. HIV-1 and the aetiology of AIDS. Lancet 341: 658–659.
Schechter, M.T., K.J.P. Craib, J.S.G. Montaner, T.N. Le, M.V. O'Shaughnessy & K.A. Gelmon, 1993c. Actiology of AIDS. Lancet 341: 1222–1223.
Schnoll, S.H., J. Karrigan, S.B. Kitchen, A. Daghestani & T. Hansen, 1985. Characteristics of coeaine abusers presenting for treatment, pp. 171–181 in Cocaine use in America: epidemiologic and clinical perspectives, 61, edited by NIDA US Dept. HHS. US Department of Health & Human Services.
Schuster, C., 1985. Coeaine use in America: epidemiological and clinical perspectives p. v in NIDA Research Monograph Series, 61, edited by NIDA US Department HHS. US Department of Health & Human Services.
Scolaro, M., R. Durham & G. Pieczenik, 1991. Potential molecular competitor for HIV. Lancet 337: 731–732.
Seligmann, M., L. Chess, J.L. Fahey et al., 1984. AIDS — an immunologic reevaluation. N. Engl. J. Med. 311: 1286–1292.
Seligmann, M., D.A. Warrell, J.-P. Aboulker et al., 1994. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343: 871–881.
Selik, R.M., H.W. Haverkos & J.W. Curran, 1984. Acquired Immune Deficiency Syndrome (AIDS) in the United States, 1978–1982. American Journal of Medicine 76 (March): 493–500.
Selik, R.M., E.T. Starcher & J.W. Curran, 1987. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1: 175–182.
Selwyn, P.A., A.R. Feingold, D. Hartel, E.E. Schoenbaum, M.H. Adderman, R.S. Klein & S.H. Freidland, 1988. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 2: 267–272.
Shenton, J., 1998. Positively False: exposing the myths around HIV and AIDS. I.B. Tauris, London/New York.
Shilts, R., 1987. And the Band Played On. St. Martin's Press, New York.
Signorile, M., 1997a. The ineredible bulk: If looks like the whole gay world is on steroids, maybe that's because it is. Out, May, p70, 72, 73, 124.
Signorile, M., 1997b. Life Outside: The Signorile report on Gay Men: Sex, Drugs, Muscles, and the Passages of Life. Harper-Collins Publishers, New York.
Simmons, T., 1995. Living on the edge. The Advocate, December 26, p. 25–28.
Sloand, E., P.N. Kumar & P.F. Pierce, 1993. Chemotherapy for patients with pulmonary Kaposi's sarcoma: benefit of filgrastim (G-CSF) in supporting dose administration. Southern Medical Journal 86: 1219–1224.
Smothers, K., 1991. Pharmacology and toxicology of AIDS therapies. The AIDS Reader 1(1): 29–35.
Soderberg, L.S., 1998. Immunomodulation by nitrite inhalants may predispose abusers to AIDS and Kaposi's sarcoma. J. Neuroimmunol. 83: 157–161.
Sonnabend, J.A., S.S. Witkin & D.T. Purtillo, 1983. A multifactorial model for the development of AIDS in homosexual men. Ann. N.Y. Acad. Sci. 437: 177–183.
Spornraft, P., M. Froschl, J. Ring, M. Meurer, F.D. Goebel, H.W. Ziegler-Heitbrock, G. Riethmuller & O. Braun-Falco, 1988. T4/T8 ratio and absolute T4 cell numbers in different clinical stages of Kaposi's sarcoma in AIDS. Br. J. Dermatol. 119(1): 1–9.
Springer Verlag, 1996, 46–96; 50 Jahre Springer — 50 Jahre Zeitzeuge, Axel Springer Verlag, Hamburg, Germany.
St. Angelo, M., 1996. Duesberg's Questions About HIV/AIDS Merit Answers. Windy City Times, April 11, p. 12.
Stewart, G.T., 1968. Limitations of the germ theory. Lancet i: 1077–1081.
Stewart, G.T., 1989. Uncertainties about AIDS and HIV. Lancet i: 1325.
Stewart, G.T., 1996. The epidemiology and transmission of AIDS: a hypothesis linking behavioural and biological determinants to time, person and place pp. 163–183 in AIDS: Virus or Drug-Induced?, vol. 5, edited by P.H. Duesberg. Kluwer Academic Publishers, Dordrecht, The Netherlands.
Stolberg, S.G., 1997. Despite new AIDS drugs, many still lose the battle. The New York Times, August 22, p. 1, A6.
Stoneburner, R.L., D.C. Des Jarlais, D. Benezra et al., 1988. A larger spectrum of severe HIV-I-related disease in intravenous drug users in New York City, Science 242: 916–919.
Tanaka, M., 1996. Abrams cautious on use of new AIDS drugs. Synapse (University of California San Francisco), October 10, p. 1, 5.
Terry, C.E. & M. Pellens, 1928. The Opium Problem. Bureau of Social Hygiene of New York.
The European Collaborative Study, 1994. Natural History of Vertically Acquired Human Immunodeficiency Virus-1 Infection. Pediatrics 94(6): 815–819.
The Lancet, 1994. Zidovudine for mother, fetus, and child: hope or poison? Lancet 344(8917): 207–209.
Thompson, M.B., J.K. Dunnick, M.E. Sutphin, H.D. Giles, R.D. Irwin & J.D. Prejean, 1991. Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice. Fundamental and Applied Toxicology 17: 159–176.
Till, M. & K.B. MacDonnell, 1990. Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine? Ann. Intern. Med. 113: 492–494.
Toltzis, P., T. Mourton & T. Magnuson, 1993. Effect of zidovudine on preimplantation murine embryos. Antimicrob. Agents Chemother. 37: 1610–1613.
Toufexis, A., 1991. Innocent victims. Time, May 13, p. 56–60.
Tubaro, E., G. Borelli, C. Croce, G. Cavallo & C. Santiangeli, 1983. Effect of morphine on resistance to infection. J. Infect. Dis. 148(4): 656–666.
Tuller, D., 1996. Uncertain life after certain death. San Francisco Chronicle, November 24, p. 1–5 zone 6.
U.S. Department of Health & Human Services, 1993. Annual emergency department data 1993. Data from the Drug Abuse Warning Network (DAWN), p. 81–110.
U.S. Department of Health & Human Services, 1994. Annual Medical Examiner data. Data from the Drug Abuse Warning Network (DAWN), 1994, p. 1–82.
US Department of Health & Human Services & Public Health Service & Substance Abuse and Mental Health Services Administration (SAMHSA), 1996. Historical estimates from the drug abuse warning network.
Veugelers, P.J., K.A. Page, B. Tindall et al., 1994. Determinants of HIV disease progression among homsexual men registered in the tricontinental seroconverter study. Am. J. Epidemiol. 140(8): 747–758.
Volkow, N.D., G.-J. Wang, M.W. Fischmann, R.W. Foltin, J.S. Fowler, N.N. Abumrad, R. Hitzemann & C.E. Shea, 1997. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature (London) 386: 827–830.
Wallace, B., 1996. "speed’ Abusers Need More and More. San Francisco Chronicle, May 31, p. A2.
Ward, J.W., T.J. Bush, H.A. Perkins et al., 1989. The natural history of transfusion-associated infection with human immunodeficiency virus. N. Engl. J. Med. 321: 947–952.
Weber, R., W. Ledergerber, M. Opravil, W. Siegenthaler & R. Lüthy, 1990. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. Br. Med. J. 301: 1362–1365.
Weil, A. & W. Rosen, 1983. Chocolate and morphine. Houghton Mifflin Co., Boston.
Weiss, R., 1991. Provenance of HIV strains. Nature (London) 349: 374.
Weiss, R. & H. Jaffe, 1990. Duesberg, HIV and AIDS. Nature (London) 345: 659–660.
Wesson, D. & D. Smith, 1985. Cocaine: treatment perspectives, in Cocaine Use in America: epidemiologic and clinical perspectives, 61, edited by N. Kozel & E. Adams. NIDA, US Dept. HHS. Washington, DC.
White House Office of National Drug Control Policy, 1998. Fact Sheet: Drug data summary. DHSS, the White House.
Whitehead, A.N., 1967. Science and the Modern World. p. 187, The Free Press, a division of Macmillan Publishing Co., Inc., New York.
Wilson, J.M., K.S. Kalasinsky, A.I. Levey et al., 1996. Striatal dopamine nerve terminal markers in human, chronic metamphetamine users. Nature Medicine 2(6): 699–703.
World Health Organisation, 1996. WHO Report No 48. Weekly Epidemiological Record (WER) 48(71): 361–368.
World Health Organization, 1995a. The Current Global Situation of the HIV/AIDS Pandemic. WHO.
World Health Organization, 1995b. WHO Report No. 45: AIDS Surveillance in Europe. AIDS Forschung 10: 603–613.
Yarchoan, R. & S. Broder, 1987. Antiretroviral therapy for AIDS. N. Engl. J. Med. 317: 630.
Yarchoan, R., J.M. Pluda, C.-F. Perno, H. Mitsuya & S. Broder, 1991. Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood 78: 859–884.
Young, I., 1995. Hell Bent... or Heavenly Scent? Continuum, p. 22–25.
Zachary, B., 1997. Confronting the crystal culture crisis. San Francisco Frontiers, July 31.
Zonona, V., 1992. Kramer vs. the World (interview with Larry Kramer). The Advocate, December 1.
About this article
Cite this article
Duesberg, P., Rasnick, D. The AIDS dilemma: drug diseases blamed on a passenger virus. Genetica 104, 85–132 (1998). https://doi.org/10.1023/A:1003405220186
- Human Immunodeficiency Virus
- Acquire Immune Deficiency Syndrome
- Recreational Drug